A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Clinical trial NCT07128251 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07128251
Sponsor: Anhui Provincial Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma (HCC)Immunotherapy PD-1 CTLA-4 TACE

Start date: 2025-08-20
Primary completion: 2028-01-30
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.